e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology in the United Kingdom. The company focuses on the discovery of cancer and degenerative diseases of the nervous system. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; ETS6103, a Phase IIb trial product for depressive disorders; and ETX1153c, a preclinical stage drug for the treatment of C. difficile infection. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
e-therapeutics plc (ETX:London)
Network Pharmacology Centre
17 Blenheim Office Park
Long Hanborough, OX29 8LN
Phone: 44 1993 880 000
Fax: 44 1993 880 207www.etherapeutics.co.uk
|No competitor information is available for ETX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.